Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.

"We are very pleased to reach 100% territorial coverage for CytoCare in Asia-Pacific. This new partnership culminates a great year for Health Robotics' CytoCare adoption and unprecedented market success versus our competition, on the heels of similar new partnerships signed this Summer and Fall in Oceania, China, Taiwan, and South East Asia. In these difficult economic times and at a moment where our competitors are in retreat and total disarray, we have increased our lead in product superiority, expanded our reach worldwide, and are now posed to reap benefits in years to come. We welcome BioRobotics to our family of strategic channel partners and look forward to host them next week, along with more than twenty (20) worldwide partners at Health Robotics' First Annual Partner Training in Trieste, Italy," stated Werner Rainer, Health Robotics' CEO.

CytoCare is the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures for Chemotherapy, Monoclonal Antibody Therapy, and Gene Therapy. While other companies have for many years made promises of robotic IV automation products and even showcased staged "smoke and mirrors" marketing demonstrations of competing solutions that were supposed to exist as far back twenty years[1] ago, the fact remains that CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous IV Admixtures, and that has been proven to work in a "live" hospital pharmacy environment, instead of just marketing brochures and theatrical shows.

"We are delighted that Health Robotics has given us this great opportunity as their exclusive strategic partner in our core market of Korea. CytoCare, the world's only real Oncology IV Admixtures Robot in existence, represents an ideal complement to BioRobotics' medical portfolio of Oncology Robotics' products and services, including Intuitive Surgical's daVinci(R) Surgery Robot. Just like Device Technologies Australia and PinnacleMed, I was very impressed with Health Robotics' technology and have received excellent references from other Asia-Pacific based daVinci(R) Surgery Robot's distribution partners, with whom we maintain regular contact. My contract negotiation meetings with Gaspar DeViedma last week were very productive and led to the execution of this very important milestone for our company", stated Bum Kyo Lee, CEO of BioRobotics.

Source:

Health Robotics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
MiRNAs can be used as a biomarker to predict disease recurrence and mortality in breast cancer patients